The aim of this review is to give an overview of lipid-related risk of atherosclerotic cardiovascular disease (ASCVD) beyond low-density lipoprotein (LDL) cholesterol. High LDL cholesterol is a key driver of ASCVD as shown in several interventional, mechanistic, observational and genetic studies. Therefore, the focus has for decades been on lowering LDL cholesterol levels. Attention is now shifting beyond LDL cholesterol towards additional risk measures. Mechanistic, observational and genetic studies support a causal role of elevated remnant particles and high lipoprotein(a) in the development of ASCVD, which has led pharmaceutical companies to develop new potential drugs targeting these lipoproteins. In the coming years results from randomised controlled trials with these drugs are expected. Furthermore, with rates of obesity, insulin resistance, diabetes and the metabolic syndrome increasing worldwide, the use of lipid measurements capturing risk in addition to LDL cholesterol is more relevant than ever. Lipoprotein(a) levels are genetically determined while remnant cholesterol levels are highly correlated to overeating, obesity and diabetes. In a future population with higher risk of ASCVD given the obesity pandemic it will have growing importance to target lipids involved in metabolic dysregulation and lipids that are genetic drivers of ASCVD.